Face psoriasis linked to increased ESRD risk, but systemic treatment may help

  • Lee E & al.
  • Sci Rep
  • 12 Nov 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients with psoriasis are at increased risk of end-stage renal disease (ESRD), although this association is not found in patients who received systemic treatment, according to a population study.

Key results

  • Psoriasis was associated with increased risk of ESRD in adjusted analysis (HR, 1.58; P<.001>
  • Psoriatic arthritis was associated with a further increased risk of ESRD in adjusted analysis (HR, 7.60; P<.001>
  • In subgroup, psoriasis was significantly associated with ESRD risk in patients who did not receive systemic treatment (HR, 1.60; P<.001 but not in patients who received systemic treatment ci>
  • Patients treated with acitretin (Soriatane) had a reduced risk of ESRD (HR, 0.576; 95% CI, 0.385-0.863) compared with patients who did not receive systemic treatment.

Study design

  • 2,121,228 adult subjects, 530,307 with psoriasis, were analysed for ESRD risk.
  • Funding: National Research Foundation of the Republic of Korea.

Limitations

  • Observational study of large database.